Abstract Number: 0219 • ACR Convergence 2023
Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab
Background/Purpose: Patients on B-cell depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting SARS-CoV-2 or suffering from…Abstract Number: 0810 • ACR Convergence 2023
Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic
Background/Purpose: The COVID-19 pandemic prompted a rapid transition to increased telehealth utilization, with many rheumatology providers replacing in-person clinical visits with telehealth visits or expanding…Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…Abstract Number: 1831 • ACR Convergence 2023
Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia
Background/Purpose: Fibromyalgia (FM) symptoms fluctuate, with exacerbation commonly associated with stressors. The COVID-19 pandemic was a cause of prolonged stress due to factors such as…Abstract Number: 2300 • ACR Convergence 2023
Outcomes of COVID-19 Before and During the Omicron Variant Period in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study Using the TriNetX Network
Background/Purpose: The global dominance of the SARS-CoV-2 Omicron variant ensued shortly after its initial identification in South Africa on November 24, 2021. The outcomes of…Abstract Number: 0133 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study
Background/Purpose: COVID-19 vaccines have been proven to be safe in healthy populations. However, data on delayed adverse effects (AEs) in people with autoimmune diseases (AIDs),…Abstract Number: 0220 • ACR Convergence 2023
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…Abstract Number: 0972 • ACR Convergence 2023
Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population
Background/Purpose: An increase in the incidence of autoimmune diseases after COVID-19 has been reported. Since many diseases exhibit population-specific causal effect sizes, we aimed to…Abstract Number: 1651 • ACR Convergence 2023
Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Background/Purpose: Previous published works have raised the concern that methotrexate (MTX) might have a negative effect on immune response upon vaccine administration. At the beginning…Abstract Number: 1832 • ACR Convergence 2023
Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital
Background/Purpose: Since its discovery in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) has ravaged the globe on an unprecedented scale. While…Abstract Number: 2316 • ACR Convergence 2023
Effect of SARS-CoV2 Infection on Disease Flares in Patients with Systemic Lupus Erythematosus: A Case-control Study
Background/Purpose: To study the effect of SARS-CoV2 infection on disease flares in patients with systemic lupus erythematosus (SLE).Methods: Patients who fulfilled the ACR or SLICC…Abstract Number: 0142 • ACR Convergence 2023
New-Onset Systemic Autoimmune Diseases Following COVID-19 Vaccination – Results from the COVAD Study
Background/Purpose: We aim to describe the profile of new-onset systemic autoimmune diseases (SAID) developed in individuals following COVID-19 vaccination and to characterize the potential risk…Abstract Number: 0221 • ACR Convergence 2023
Post-COVID-19 Autoimmune Serologies and Immunophenotypes
Background/Purpose: Autoimmunity after COVID-19 infection has been reported. We examined connective tissue disease (CTD) symptoms and autoantibodies, SARS-CoV-2 serologies, and T and B cell immunophenotypes…Abstract Number: 1064 • ACR Convergence 2023
Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination
Background/Purpose: COVID-19 has increased the mortality rates among rheumatic patients, mainly those immunocompromised or with underlying comorbidities. During the COVID-19 vaccine development, patients on immunomodulatory…Abstract Number: 1672 • ACR Convergence 2023
Association of COVID-19 Vaccinations with Flares of Systemic Rheumatic Disease: A Case-Crossover Study
Background/Purpose: Fear of flare contributes to COVID-19 vaccine hesitancy in patients with systemic rheumatic diseases (SRD). Accurately ascertaining post-vaccine SRD flares and differentiating them from…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 38
- Next Page »